AstraZeneca Eyes Bristol Myers: A $300B Merger Nobody Greenlit Yet
The two companies together carry a combined market capitalisation approaching $300 billion.
AstraZeneca Eyes Bristol Myers: A $300B Merger Nobody Greenlit Yet
AstraZeneca has held exploratory talks about acquiring Bristol-Myers Squibb in what would rank among the largest pharmaceutical mergers in corporate history, Bloomberg reported Wednesday, citing people familiar with the matter.
The two companies together carry a combined market capitalisation approaching $300 billion. AstraZeneca, headquartered in Cambridge and listed in London and Stockholm, has spent the past decade transforming itself from a mid-tier drugmaker into one of oncology's dominant forces — a repositioning built on the back of its cancer portfolio and, more recently, its COVID-19 vaccine revenue. Bristol-Myers Squibb brings Opdivo, Eliquis, and a deep immunology pipeline that would significantly expand AstraZeneca's reach into blood cancers and cardiovascular disease.
No deal has been agreed, and it remains unclear whether Bristol-Myers Squibb's board has engaged formally with any approach. Megamergers of this scale routinely attract antitrust scrutiny on both sides of the Atlantic, and European regulators have shown little appetite for consolidation that reduces competition in therapeutic categories where patient choice is already limited.
What is clear is that AstraZeneca Chief Executive Pascal Soriot has consistently signalled ambition beyond organic growth, and the pharmaceutical sector is entering a period of patent cliff anxiety — blockbuster drugs losing exclusivity, generics entering the market, revenue forecasts narrowing. A deal of this magnitude would buy time, pipeline, and pricing power simultaneously.
Whether Brussels and Washington allow it is an entirely separate question.
